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Abstract.  The synovium from patients  with rheuma- 
toid arthritis  (RA) and LEW/N rats with streptococcal 
cell wall (SCW) arthritis,  an experimental model 
resembling RA, is characterized by massive prolifera- 
tion of synovial connective tissues and invasive de- 
struction of periarticular bone and cartilage.  Since 
heparin binding growth factor (HBGF)-I, the precursor 
of acidic fibroblast growth factor (FGF),  is a potent 
angiogenic polypeptide and mitogen for mesenchymal 
cells, we sought evidence that it was involved in the 
synovial pathology of RA and SCW arthritis. 
HBGF-1 mRNA was detected in RA synovium using 
the polymerase chain reaction technique,  and its prod- 
uct was immunolocalized intracellularly  in both RA 
and osteoarthritis  (OA) synovium.  HBGF-1 staining 
was more extensive and  intense in synovium of RA 
patients than OA and correlated with the extent and 
intensity of synovial mononuclear cell infiltration. 
HBGF-1 staining also correlated with c-Fos protein 
staining.  In SCW arthritis,  HBGF-1 immunostaining 
was noted in bone marrow,  bone, cartilage,  synovium, 
ligamentous and tendinous structures,  as well as vari- 
ous dermal structures  and developed early in both T-cell 
competent and incompetent rats.  Persistent high level 
immunostaining  of HBGF-1 was only noted in T-cell 
competent rats like the disease process in general. 
These observations implicate HBGF-1 in a multitude 
of biological functions in inflammatory joint diseases. 
H 
EPARIN binding  growth  factor (HBGF)1-1, the pre- 
cursor of acidic fibroblast growth factor (FGF), is a 
potent polypeptide mitogen  for mesenchymal and 
neuroectoderm-derived cells (Thomas,  1987; Lobb et al., 
1986; Burgess and Maeiag,  1989). HBGF-1 is a member of 
a larger HBGF family of  polypeptides that presently includes 
basic FGF and  the oncogenes int-2  (Dickson and  Peters, 
1987), hst/KS (Taira et al.,  1987; Delli Bovi et al.,  1987), 
FGF-5 (Zhan et al., 1988), FGF-6 (Marics et al.,  1989) and 
keratinoeyte growth factor (KGF) (Finch et al.,  1989). The 
amino acid sequences of bovine and human HBGF-1 have 
been determined (Gimenez-Gallego  et al., 1985; Burgess et 
al.,  1986; Gautschi-Sova  et al.,  1986),  and complementary 
DNA clones encoding human  HBGF-1 have been isolated 
(Jaye et al.,  1986).  The HBGF-1 polypeptide has been ex- 
tracted  from  bone matrix  (Huschka  et  al.,  1986),  brain 
(Thomas et al., 1984), retina (Baird et al., 1985), and kidney 
(Gautschi-Sova et al., 1987), and stimulates the proliferation 
of chondrocytes  (Burgess  and  Maciag,  1989),  calvaria- 
derived osteoblastic cells (Canalis et al., 1987; Rodan et al., 
1987),  and synovial fibroblast-like  cells in vitro  (Remmers 
1. Abbreviations used in this paper: FGE fibroblast growth factor;  H and 
E, hematoxylin and eosin; HBGF, heparin binding growth factor; OA, os- 
teoarthritis, PCR,  polymerase chain reaction; RA,  rheumatoid arthritis; 
SCW, streptococcal  cell wall. 
et al.,  1989).  In addition,  HBGF-1 not only stimulates  en- 
dothelial  cell proliferation  in  vitro  (Burgess  and  Maciag, 
1989) but is a potent angiogenic factor in vivo (Folkman and 
Klagsbrun,  1987; Thompson et al.,  1988). 
The  synovium  from  patients  with  rheumatoid  arthritis 
(RA) and LEW/N rats with streptococcal cell wall (SCNV)  ar- 
thritis,  an experimental  model resembling RA, is character- 
ized by diffuse and nodular mononuclear cell infiltration and 
pronounced  hyperplasia  of the  stromal  connective tissues 
comprised  of fibroblast-like  cells  and  new blood vessels 
(Harris,  1976;  Fassbender,  1983;  Bromley  and  Woolley, 
1984a;  Bromley and Woolley,  1984b;  Wilder et al.,  1987; 
Yocum et al.,  1988).  The synovial fibroblast-like  cells and 
new blood vessels, and to a lesser extent macrophages and 
osteoclasts,  are the predominant cell populations  at sites of 
cartilage  resorption  and  bone  erosion.  This  high-grade 
proliferative  and invasive disease process resembles a locally 
invasive tumor (Harris,  1976; Fassbender,  1983; Hamilton, 
1983; Haraoui et al.,  1985; Wilder et al.,  1987; Yocum et 
al., 1988; Remmers et al., 1989; Lafyatis et al., 1989a; Case 
et al.,  1989a,b). In contrast to malignantly  transformed tis- 
sues, the tumorlike phenotype of the synovial tissues is not 
constitutive,  and  paracrine  factors,  elaborated locally and 
systemically by inflammatory cells, appear necessary to in- 
duce proliferation  and  invasion  by synovial  mesenchymal 
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play important roles in this process (Lafyatis et al.,  1989a,b; 
Remmers et al.,  1989). Because angiogenesis is a prominent 
feature of the destructive process in RA and SCW arthritis, 
we analyzed the synovium of patients with RA, osteoarthritis 
(OA) and t~f SCW-injected rats for the presence of HBGF-1. 
We present evidence that implicates HBGF-1 in these disease 
processes. 
Materials and Methods 
Tissue Specimens and Induction of  Arthritis 
Synovia were obtained intraoperatively from 20 RA and 11 OA patients at 
the time of arthroscopic biopsy or total joint replacement. 20 patients with 
RA met the 1987 revised criteria for the classification of RA (Arnett et al., 
1988).  No attempt was made to segregate RA or OA patients on basis of 
duration  of disease  or  disease  activity.  Specific  pathogen-free  inbred 
LEW/N  female rats were obtained from Harlan Sprague Dawley (Indi- 
anapolis, IN) and congenitally athymic nude LEW.rnu/rnu rats were ob- 
tained from the Small Animal Section, Veterinary Resources Branch, Na- 
tional Institutes of Health, Bethesda, MD. Animals were housed in cages 
with filter tops (Lab Products Inc., Maywood, NJ) in an environment free 
of known microbial pathogens. The rats  were 'x,6  wk old and weighed 
80-100 g at the initiation of each experiment. The preparation of cell wall 
peptidoglycan-polysaccharide  fragments from group A streptococci and the 
induction of polyarthritis  were  done  as  described  in  detail  previously 
(Wilder et al.,  1982).  Briefly,  a  sterile aqueous suspension of sonicated 
SCW fragments in PBS, pH 7.4 was injected intraperitoneally into rats at 
a dose equivalent to 20/~g of cell wall/g body weight. This dose has been 
shown previously to induce acute and chronic polyarthritis in LEW/N fe- 
male rats, and acute polyarthritis in athymic nude LEW.rnu/rnu rats with 
nearly 100% incidence. Rats injected with SCW (day 0) were killed in pairs 
at days 1-4 and 28; i.e., through the preclinical and clinical stages of  disease 
until the development of maximal clinical arthritis.  Hindfoot specimens 
were  preserved  in  10%  formalin,  decalcified in  EDTA,  embedded  in 
paraffin, and sectioned (6/~m) onto gelatin-coated microscope slides. Hu- 
man synovial specimens were prepared similarly, but the decalcification 
procedure was not necessary. 
Purification of  HBGF-1 Antibody 
Polyclonal antiserum against HBGF-I was prepared in a rabbit according 
to  Lerner  (1981) and  affinity-purified on  recombinant human  HBGF-I 
(Forough, R., D. Roeder, J. A. Thompson, D. Seandella, and T. Maciag, 
unpublished observations) coupled to cyanogen bromide-activated Sepha- 
rose 4B  (Pharmacia  Fine Chemical,  Uppsala,  Sweden) (Johnstone and 
Thorpe, 1987). For affinity purification,  polyclonal antibody against HBGF-1 
was added to the HBGF-1-Sepharose conjugate and incubated at room tem- 
perature for 2 h. The suspension was packed in a  1 x  lO-cm column and 
washed with phosphate buffer (20 mM sodium phosphate, pH 7.3, with 0.5 
M NaCl) until the OD2s0 returned to baseline. The antibody bound to the 
affinity column was eluted with thiocyanate buffer (3 M KSCN with 0.5 M 
ammonium hydroxide) and dialyzed against several changes of cold PBS. 
Western Blot Analysis of  AJ~inity-purified Antibody 
against HBGF-I 
Recombinant human HBGF-1  and 2 (20 ng/lane) were run on 15% poly- 
acrylamide  gel  in  reducing conditions.  Proteins  were  transferred dec_ 
trophoretically to a nitrocellulose membrane (0.2 #m pore size; Schleicher 
& Schuell, Keene, NH) in transfer buffer (25 mM Tris,  192 mM glycine, 
0.02%  SDS, 20% methanol~ for 2 h at 400 mA (Towbin et al.,  1979).  The 
filter was then blocked by incubation in 50 mM Tris-HCl-150 mM NaCI, 
pH 7.4 (TBS) containing 5% BSA for 2  h.  The blot was incubated with 
affinity-purified HBGF-1  antibody (50/~g/ml) in TBS containing 5% BSA 
for 1 h. After washing four times in TBS with 0.05 % Triton X-100, the filter 
was  incubated  with  5  x  105  cpm  of  125I-protein  A/ml  (Calbiochem- 
Behring Corp., San Diego, CA) as described (Friesel et al., 1989). The blot 
was washed four times in TBS containing 0.05 % Triton X-100 and air dried. 
Binding of 125I-protein A was visualized by autoradiography with Kodak 
XAR films at  -80°C for 10 h. 
lmmunohistochemistry 
lmmunoperoxidase staining with Vecstatin ABC kit (Vector Laboratories, 
Inc., Burlingame, CA) followed the manufacturer's suggested protocol (Hsu 
and Ree,  1980,  Hsu et al.,  1981). All subsequent procedures were per- 
formed at room temperature. The sections were deparaffinized. Endogene- 
ons peroxidase activity was exhausted by incubating in 0.3% peroxide in 
r,~thanol for 45 rain. The sections were preincubated with 0.1% BSA in 
PBS for 20 rain and with diluted goat serum (1:66.7) for 20 rain followed 
by incubation in a humid chamber with affinity-purified HBGF-1 antibody 
(50 tzg/ml), anti-HBGF-I antibody that was absorbed extensively on HBGF- 
i-Sepharose (affinity-negative  IgG)  50 #g/ml or purified rabbit lgG (50 
p.g/ml; Jackson Immunoresearch Laboratories, Inc., West Grove, PA). Af- 
ter 30 rain, the sections were washed in PBS and incubated with biotinylated 
goat anti-rabbit IgG for 30 rain, the sections were further washed with PBS 
and incubated with an avidin and biotinylated horseradish peroxidase com- 
plex. Finally, the sections were washed and color was developed by immers- 
ing  sections in  a  solution of 0.05%  wt/vol 3,3-diaminobenzidine tetra- 
hydrochloride (Sigma Chemical Co., St. Louis, MO), 0.04% wt/vol nickel 
chloride, and 0.01% hydrogen peroxide in 0.05 M Tris pH 7.4 for 2-7 rain. 
The sections were counterstained with 0.5% light green SF (Roboz Surgical 
Instrument Co. Inc., Washington, DC). 
Anti-e-Fos protein immunostaining employed a commercially available 
affinity-purified immunoglobulin  (OP-11-821;  Cambridge  Research Bio- 
chemicals, Valley  Stream,  NY)  made in sheep by immunization with a 
synthetic peptide corresponding to amino acid sequence: Met-Pbe-Ser-Gly- 
Phe-Asn-Ala-Asp-Tyr-Glu-AlaoSer-Ser-Ser-Arg-[Cys]  derived from a con- 
served region of both murine and human c-Fos (van Straaten et al., 1983). 
Optimal staining was achieved at a  concentration of 25  /zg/ml. Control 
slides were incubated with an equal concentration of sheep IgG (Chrom- 
pure, Jackson Immunoresearch Laboratories, Inc.), or with the specific an- 
tibody preincuhated with a 100x molar excess of the immunogenic peptide. 
These were negative in all cases. Positive staining was indicated by brown- 
ish black deposits. Control stains with affinityonegative  IgG,  rabbit IgG, 
sheep IgG, or the specific antibody absorbed with the Fos peptide were uni- 
formly negative in all cases. 
For  each  tissue  specimen, the extent and  intensity of staining with 
HBGF-I antibody and c-Fos antibody were graded on a scale of 0-4+ by 
a blinded observer on two separate occasions using coded slides and an av- 
erage score calculated. The observer assessed all tissue on the slides to as- 
sign the scores. Thus, a 4+ grade implies that all staining was maximally 
intense throughout the tissue specimen, while 0  implies that staining was 
absent throughout the specimen. Particular attention was also given to the 
histologic structures that stained most intensely. Mononuclear cell infiltra- 
tion was assessed similarly on hematoxylin and eosin (H and E) stained sec- 
tions cut from the same paraffin blocks used for antibody staining. Thus, 
a 4+ grade implies that all tissue was intensely infiltrated with mononuclear 
cells,  while  0  implies  that  mononuclear  cell  infiltration  was  absent 
throughout. 
RNA Isolation 
Tissue specimens were either flash-frozen in liquid nitrogen for subsequent 
storage, or immediately homogenized in lysiog buffer with a homogenizer 
(Brinkmann Instruments, Westbury, NY) for storage at -70°C or immedi- 
ate use; specimens stored in liquid nitrogen were later homogenized in lys- 
ing buffer as frozen pieces. RNA was isolated by the method of Chomczyn- 
ski and Sacchi (1987);  for tissue specimens, the second extraction step was 
replaced by proteinase K digestion followed by multiple extractions with 
phenol-chloroform in a microfuge tube. RNA was aliquotted and stored as 
ethanol precipitates at  -20°C. 
Southern Blot Analysis of Polymerase Chain Reaction 
of  Reverse-transcribed RNA 
Total RNA (1 /~g) was extracted from synovial tissues of RA patients and 
reverse-transcribed. The eDNA fragments were amplified for 40 cycles with 
the polymerase chain reaction (PCR) technique (Saiki et al., 1988;  Stoflet 
et al., 1988) using a pair of sequence specific primers for I-IBGF-I: nueleo- 
tides 166-186 on (+) strand and 483-503 on (-) strand (Jaye et al., 1986). 
Specifically,  the samples were heated at 94"C for 1 min to denature the 
eDNA, cooled to 52°C for 2 rain to anneal the primers and heated to 72"C 
for 3 min to extend the annealed primers with Taq DNA polymerase. PeR 
amplified products were resolved on a composite gel of 2% NuSieve and 
1% agarose (Bethesda Research Laboratories, Gaithersburg, MD) in Tris- 
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sis of PCR-amplified products 
of  reverse-transcribed  RNA 
isolated from synovial tissues 
of RA patients. Total RNA (1 
/~g) was extracted from syno- 
vial  tissues  of  RA  patients 
and  reverse-transcribed.  The 
HBGF-1 cDNA fragments  were 
amplified for 40 cycles with 
the  PCR  technique  using  a 
pair of sequence specific pri- 
mers: nucleotides 166-186 on 
(+)  strand  and  483-503  on 
(-) strand. The expected pro- 
duct (336 bp) was demonstrat- 
ed by hybridization with  p2P]-labeled HBGF-1 cDNA  (lane I). 
PCR-amplified products of reverse-transcribed RNA isolated from 
chicken gizTard (lane 2) served as a control. 
borate-EDTA  buffer  and capillary  transferred  to a nitrocellulose  membrane. 
For hybridization,  [32p]-labeled HBGF-I isolated  from  a human brain stem 
eDNA library  (R. Forough and T. Maeiag, unpublished observation)  was 
used, and corresponded  to the nucleotide  sequence  reported  by Jaye  et al. 
(1986). 
Statistical Analysis 
Analyses of data were performed using the Wilcoxon rank-sum test and 
Spearman's rank correlation  (Remington  and Schork, 1985). 
Results 
Southern Blot Analysis of  PCR-amplified Products of 
Reverse-transcribed RNA Isolated from Synovial 
Tissues of  RA Patients 
Northern blot analysis of poly A-selected RNA extracted 
from RA  and  OA  synovium failed to  detect the  HBGF-1 
mRNA transcript. As an alternative, RNA purified from RA 
synovium was reverse transcribed and the eDNA fragments 
amplified using the PCR technique.  Products of the PCR 
were subjected to gel electrophoresis and validated by South- 
ern blot analysis. As shown in Fig.  1, RNA from RA syno- 
vium expressed HBGF-1 mRNA transcripts.  The expected 
size band (336 bp) was detected by hybridization with [32p]_ 
labeled HBGF-1 isolated from a human brain stem eDNA li- 
brary (Fig.  1, lane/). 
HBGF-1 lmmunostaining of  Synovium from Patients 
with RA and OA 
To determine whether the HBGF-1  mRNA  transcript was 
translated and to identify the microanatomical location of  the 
polypeptide,  we  immunohistochemically  stained  synovial 
tissues.  The affinity-purified HBGF-1 antibody was used to 
stain synovium from patients with RA and OA. Western blot 
analysis of the affinity-purified antibody demonstrated that 
HBGF-1 antibody recognized HBGF-1 but not HBGF-2 (ba- 
sic FGF) (Fig. 2). This also occurred with exaggerated con- 
centrations of HBGF-2.  Furthermore, the antibody recog- 
nized  between  1  to  5  ng  HBGF-1  per  lane  loaded  onto 
SDS-PAGE, indicating that the antibody had a relatively high 
affinity for HBGF-1. As shown in a representative synovial 
tissue section (Fig. 3), diffuse and intense intracellular stain- 
ing was observed within the synovial lining cell layer (Fig. 
3, A and C).  Prominent HBGF-1 polypeptide staining was 
also observed in the sublining stromal fibroblast-like cells 
(Fig. 3, A, C, and D), vascular endothelial cells (Fig. 3 D) 
and inflammatory cells (Fig. 3, A, C, and D). In addition to 
the  intense  cytoplasmic  staining,  many  cells  appeared  to 
show nuclear staining as well (e.g., Fig. 3 C, inset). Control 
staining with nonspecific rabbit IgG (Fig.  3 B) or afffinity- 
negative IgG was absent in all cases. Synovial tissue sections 
from patients with OA,  in sharp contrast, stained strongly 
only  on  the  lining  cell  layer and  sublining  vascular  en- 
dothelial cells (Fig. 3, E and F). Stromal fibroblast-like cells 
appeared to stain very weakly (Fig.  3, E  and F). 
Statistical Analysis of  HBGF-1 Immunostaining 
In Vivo 
The extent and intensity of staining with HBGF-1 antibody 
was graded 0-4+  by a blinded observer on 20 RA and  11 
OA synovial specimens. HBGF-1 immunostaining was more 
extensive and intense in synovium of RA patients than in that 
of OA patients (P < 0.05; Wilcoxon rank-sum test) as shown 
in Fig. 4 A. That is, RA specimens showed much more syno- 
vial sublining cell staining than OA specimens.  Moreover, 
there was a  significant correlation (r =  0.92; P  =  0.0001; 
Spearman's rank correlation) between the extent and inten- 
sity of staining with HBGF-1 antibody and the extent and in- 
tensity of mononuclear cell infiltration (assessed on H and 
E-stained sections) in synovium of RA patients (Eig. 4 B). 
HBGF-1 lmmunostaining in SCW-Injected Euthymic 
LEW/N and Athymic LEW. rnu/rnu Rats with Arthritis 
The kinetics of positive anti-HBGF-1 immunostaining in the 
synovium were examined in SCW injected euthymic LEW/N 
and athymic LEW.rnu/rnu rats. Within 24 h of SCW admin- 
istration, both rat strains developed erythema and swelling 
of peripheral joints. Histologically, the acute inflammation, 
Figure 2. Western blot analysis of affinity-purified  antibody against 
HBGF-1. Recombinant human HBGF-1 and 2 were processed for 
Western blot as described in the text. The figure shows autoradio- 
gram visualizing proteins that were separated on a 15% polyacryl- 
amide gel, transferred  to a nitrocellulose  membrane, and probed with 
afffinity-purified  HBGF-I antibody. 
Sano et ai. HBGF-I in Rheumatoid Synovium  1419 Figure 3. Representative  HBGF-I immunopemxidase-stained  seetious of synovium  from patients with RA and OA. I-IBGF-1 was stained using 
affinity-purified  HBGF-1 antibody (50 ttg/ml) as described in Materials and Methods. Positive  staining is indicated by brownish  black deposits. 
Control staining with rabbit IgG or affinity-negative  IgG was uniformly negative. A, C, and D Representative RA synovium stained with 
HBGF-I antibody. (B) RA synovium stained with rabbit IgG demonstrating negative staining. E and F Representative  OA synovium stained 
with HBGF-1 antibody. The labels denote synovial lining cell layer (SL), sublining stromal tissue cells (SN), and blood vessels (BV). Bars, 
(A-F) 100/zm; (inset) 10/zm. 
which reflects synovial microvascular injury, is characterized 
by edema, fibrin deposition in the joint space and synovium, 
and cellular infiltration by granulocytes and macrophages. 
This initial phase of disease reaches maximal severity at day 
3 and substantially subsides over the next week (Wilder et 
al.,  1982; Allen et al.,  1985; Wilder et al.,  1987). 
By day 1 after SCW injection, anti-HBGF-1 staining was 
readily demonstrated. The synovial lining cell layer, synovial 
stromal fibroblast-like cells and blood vessels, periwa~ular 
inflammatory cells, chondroeytes and numerous cells within 
the bone matrix and bone marrow stained intensely (Fig. 5 
B). The extent and intensity of staining was similar in the eu- 
thymic and athymic rats at day 3 (Fig. 5 C). Control rats oc- 
casionally exhibited weak staining in dispersed cells within 
the synovium, bone matrix and bone marrow (Fig. 5 A). 
A  thymic-dependent phase  of disease  develops  in  eu- 
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l~gure 4. Statistical  analysis of HBGF-I immuno- 
staining in vivo. (A) Extent and intensity  of staining 
with HBGF-I antibody in synovium from patients 
with RA and QA. The extent and intensity  of stain- 
ing with I-IBGF-1 antibody was graded 0-4+ by a 
blinded observer on synovial specimens from 20 
RA and 11 OA patients. HBGF-1 immtmostaining 
was more intense  and diffuse  in synovium  of  RA pa- 
tients (e) than in that of OA patients (o) (P < 0.05; 
Wilcoxon rank-sum  test). (B) Correlation between 
extent and intensity of staining with HBGF-I anti- 
body and extent and intensity of mononuclear cell 
infiltration  in synovium  from patients with RA. The 
extent and intensity  of mononuclear  cell infiltration 
was graded 0-4+  on hematoxylin  and eosin sec- 
tions by a blinded  observer. The extent  and intensity 
of staining with HBGF-1 antibody on synovium 
from 20 RA patients was significantly  correlated (r 
= 0.92; P = 0.0001; Spearman's rank correlation) 
to the  extent and  intensity of mononuclear cell 
infiltration. 
thymic, but not athymic, rats  14-28 d after injection. It is 
characterized by  intense  synovial-lining cell proliferation 
and villus formation, infiltration  of  the sublining synovial tis- 
sue by lymphocytes and macrophages, and proliferation of 
fibroblast-like cells and blood vessels. Marginal erosions de- 
velop during this phase at the junctions of synovium with 
bone and cartilage, and eventually destroy the more severely 
involved joints  (Wilder et al.,  1982;  Allen et al.,  1985; 
Wilder et al.,  1987). 
During the chronic phase, joints from euthymic (Fig. 5, D 
and E), but not athymic (Fig. 5 F),  rats stained intensely 
with anti-HBGF-1. Staining was noted in the synovial lining 
cell layer, sublining stromal cells, blood vessels, cartilage 
chondrocytes, bone matrix cells, and numerous bone mar- 
row cells, as well as ligamentous and tendinous structures. 
As observed in the rheumatoid tissues, many cells appeared 
to show nuclear, as well as cytoplasmic staining (Fig. 5 E, 
inset). In addition to the staining of connective tissue and 
bone, both SCW injected euthymic and athymic rats with ar- 
thritis showed intense I-IBGF-1 staining in the skin. Interest- 
ingly, cells in the epidermis, as well as blood vessels and hair 
follicles in the dermis, stained intensely (Fig. 5 H). Control 
rats not injected with SCW did not stain with HBGF-1 anti- 
body in the skin (Fig. 5 G). 
lmmunodetection of the c-Fos Polypeptide in Synovium 
from Patients with RA and OA 
Protooncogenes such as c-myc are expressed in synovium of 
rats with SCW arthritis as well as synovium from patients 
with RA (Case et al., 1989a,b). These genes are usually ex- 
pressed in cells committed to mitosis or activation (Miiller 
and Wagner, 1984) and play an important role in the control 
of cell proliferation (Miiller et al.,  1984;  for review,  see 
Johnson and McKnight, 1989). As shown in a representative 
RA synovial tissue section, extensive and intense c-Fos spe- 
cific nuclear staining was observed within the synovial lining 
cell layer (Fig. 6, A, C, and D).  Prominent c-Fos protein 
staining was also observed in the sublining stromal fibro- 
blast-like cells (Fig. 6, A and C), vascular endothelial cells 
(Fig. 6 A), and inflammatory cells (Fig. 6, A and C). Control 
staining with the specific antibody absorbed with a  100x 
molar excess of  the immunogenic peptide (Fig. 6 B) or sheep 
IgG (Fig. 6 F) was negative in all cases. Synovial tissue sec- 
tions from patients with OA, in sharp contrast, stained at rel- 
atively low levels on the synovial lining cell layer, sublining 
vascular endothelial cells, and stromal fibroblast-like cells 
(Fig. 6 E). 
Statistical Analysis of  c-Fos Protein Immunostaining 
In Hvo 
The  extent and intensity of staining with anti-c-Fos  was 
graded 0-4+ by a blinded observer on 18 RA and 11 OA sy- 
novial specimens. The immunostaining with anti-c-Fos was 
more extensive and intense in the synovium of RA patients 
than in that of  OA patients (P < 0.01; Wilcoxon rank-sum test) 
as shown in Fig. 7 A. Moreover, there was a significant  corre- 
lation (r =  0.71, P  =  0.0024;  Spearman's rank correlation) 
between the extent and intensity of staining and the extent 
and intensity of mononuclear cell infiltration of RA patients 
(Fig. 7 B). 
Discussion 
Although it is generally accepted that the genesis of arthritis 
involves the complementary interaction between the path- 
ways initiated by the inflammatory response and angiogene- 
sis  (Folkman and Klagsbrun,  1987; Folkman,  1989),  the 
molecular basis for the initiation of the angiogenic response 
has eluded investigators (Maciag, 1989). In this manuscript, 
we  have  provided  experimental  evidence  demonstrating 
high level immunodetection of the angiogenic polypeptide, 
HBGF-1, in synovium from RA patients (Fig. 3). Immuno- 
staining in OA, a low-grade synovial fibroproliferative joint 
disease, was much less prominent (Figs. 3 and 4 A). The 
presence of the HBGF-1  mRNA transcript in RA synovial 
tissue was confirmed by PCR technique (Fig. 1). Further, we 
documented the kinetics of anti-HBGF-1 polypeptide stain- 
ing in an arthritic rat model and demonstrated that the persis- 
tent staining of HBGF-1, like the disease itself, was T-cell de- 
pendent (Fig. 5). Statistical analysis suggested that the extent 
and intensity of human HBGF-1 polypeptide immunostain- 
ing in RA tissue correlated with the extent and intensity of 
Sano et al.  HBGF-I in Rheumatoid Synovium  1421 The Journal of Cell Biology, Volume  I I0,  1990  1422 Figure 6.  Representative  c-Fos immunoperoxidase-stained  sections  of synovium from patients  with RA and OA. c-Fos oneopmtein was 
stained  using afffinity-purified anti-c-Fos antibody (25 #g/ml) as described in Materials  and Methods.  Positive  staining  is indicated  by 
brownish black deposits.  Control staining with the specific antibody absorbed with the immanogenic peptide or sheep IgG (25 tLg/ml) was 
uniformly negative. (A, C, and D) Representative  RA synovium stained with anti-c-Fos antibody. (B) RA synovium stained with anti--c-Fos 
antibody absorbed with the immunogenic peptide.  (E) Representative  OA synovium stained with anti-e-Fos antibody.  (F) OA synoviurn 
stained  with sheep IgG. The labels  denote synovial lining  cell  layer (SL) and sublining  stromal  tissue cells  (SN).  Bar,  100 i~m. 
Figure 5.  HBGF-1 immunostaining  in SCW injected euthymic LEW/N and athymic LEW.mu/rnu rats. Sections were stained as described 
in Materials and Methods with affinity-purified HBGF-1 antibody (50/xg/rnl). Positive staining is indicated by brownish-black deposits. Control 
staining with affinity-negative IgG or rabbit IgG was uniformly negative. A shows a hindfoot joint from a non-cell wail-injected  euthymic 
LEW/N rat. B shows a representative hindfoot joint from SCW-injeoed euthymic LEW/N rat with acute arthritis at day 3. C shows a hindfoot 
joint from a representative SCW injected athymic LEW.mu/mu rat with acute arthritis at day 3. D and E show a representative hindfoot joint 
from SCW-injected euthymic LEW/N rat with chronic arthritis  at day 28. (F) Hindfoot joint from a representative  SCW injected athymic 
LEW.mu/rnu rat without arthritis  at day 28. (G and H) Hindfoot skin from a non-cell wall-injected  and a SCW-injeeted euthymic LEW/N 
rat with chronic arthritis at day 28, respectively. The labels denote cartilage (C), synovial lining cell layer (SL), subsynovial tissue (SN), bone 
(B), bone marrow (BM), blood vessels  (BV), epidermis  (ED),  dermis (D),  and hair follicle (HF). Bars,  (A-H)  100 tan;  (inset)  10 tan. 
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Figure  7. Statistical analysis of c-Fos protein im- 
munostaining in vivo. (,4) Extent and intensity of 
staining with anti-c-Fos  antibody in  synovium 
from 18 RA and 11 OA patients: c-Fos protein im- 
munostaining was more extensive and intense in 
synovium  of  RA patients (e) than in that of  OA pa- 
tients (o) (P < 0.01; W'flcoxon  rank-sum test). (B) 
Correlation between extent and intensity of stain- 
ing with anti-c-Fos antibody and extent and inten- 
sity of mononuclear cell infiltration in synovium 
from patients with RA. The extent and intensity of 
staining with anti-c-Fos  antibody on synovium 
from 18 RA patients was significantly correlated 
(r = 0.71; P  = 0.0024; Spearman's rank correla- 
tion) to the extent and intensity of mononuclear 
cell infiltration. 
the inflammatory  response as measured by mononuclear cell 
infiltration in the synovium (Fig. 4 B). 
The synovium in RA tissue and in the experimental animal 
model, LEW/N rat SCW-induced arthritis, is characterized 
by exuberant hypertrophy and hyperplasia of the normally 
thin, delicate synovium, resulting primarily from prolifera- 
tion of stromal fibroblast-like mesenchymal cells (synovio- 
cytes) and new blood vessels. These cells, as well as macro- 
phages and osteoclasts, are the predominant cell populations 
at the sites of cartilage resorption and bone erosion in dis- 
eased joints, where they directly mediate articular destruc- 
tion (Bromley and Woolley, 1984a; Yocum et at., 1988). The 
observations that freshly explanted synoviocytes from rheu- 
rnatoid and SCW arthritic joints (a) proliferate rapidly in 
vitro; (b) do not undergo contact inhibition, but rather form 
foci; and (c) grow under anchorage-independent conditions 
(Yocum et at., 1988; Lafyatis  et at., 1989a), support the sug- 
gestion  that  the  aggressive  invasiveness  of  the  highly 
proliferative  lesion  resembles  a  localized,  nonmetastatic 
neoplasm (Harris, 1976; Fassbender, 1983; Hamilton, 1983; 
Haraoui et at.,  1985;  Wilder et el.,  1987; Yocum et el., 
1988).  Moreover, synovial tissues from both patients with 
RA (Brinckerhoff and Harris,  1981) and rats with SCW ar- 
thritis (Yocum et at., 1988) form short-lived tumorlike nod- 
ules when implanted in nude, athymic mice. These data sug- 
gest  that  synoviocytes may  exhibit  properties  generally 
associated with malignant tumor cells. 
Since growth of tumors depends on angiogenesis (Folk- 
man, 1989) and angiogenesis is a central feature of synovial 
lesions in RA (Folkman and Klagsbrun, 1987) and SCW ar- 
thritis in the rat (Yocum et at., 1988),  we reasoned that an- 
giogenic polypeptide growth factors may be present at high 
levels  in these tissues. The HBGF family of peptides has 
gained general acceptance as initiators of angiogenesis, nota- 
bly during  development (Folkman and  Klagsbrun,  1987; 
Burgess and Maciag, 1989).  Because anti-HBGF-1 staining 
correlated  with  severity of the  inflammatory process,  as 
reflected by the extent and intensity of mononuclear cell 
infiltration, we suggest that HBGF-1 may participate in the 
induction of neovascularization in the synovia of patients 
with RA and rats with SCW arthritis. Alternatively, since 
other polypeptide growth factors and cytokines induce angio- 
genesis in vivo (Folkman and Klagsbrun, 1987), these agents 
may also participate in the arthritic process. 
Protooncogenes such as c-myc are expressed at high levels 
in synovium from RA and rats with SCW arthritis, compared 
to OA or normal rat synovium, respectively (Case et al., 
1989a,b).  In addition, we have also shown in the present 
study that anti-c-Fos staining in synovium from RA patients 
is more intense than synovium from OA patients (Fig. 6 and 
7).  Interestingly, HBGF-1  induces c-myc and c-fos expres- 
sion in fibroblast cultures (Miiller et al., 1984) and c-fos and 
c-myc play a prominent role in cellular growth and differenti- 
ation (Johnson and McKnight, 1989).  Moreover, the HBGF 
prototypes stimulates tyrosine kinase activity (Coughlin et 
al., 1988; Friesel et al., 1989) and may therefore play a role 
in the stimulation of rheumatoid synovial stromal fibroblast- 
like  mesenchymal  cell  proliferation  and  angiogenesis 
through the induction of protooncogenes such as c-myc and 
c-fos . 
HBGF-1 also induces high levels of  both plasminogen acti- 
vator and collagenase activities in capillary endothelial cells 
in vitro (Gross et at., 1983; Moscatelli and Rifkin, 1988) and 
potentiates interleukin-l-induced collagenase production in 
chondrocytes (Chandrasekhar and Harvey,  1989).  The ex- 
pression of  plasminogen activator and collagenase is elevated 
in the synovium of RA patients and SCW rats (Dayer et at., 
1976; Decker et at., 1984). Thus, we suggest that the expres- 
sion of these proteolytic enzymes during the genesis of RA 
and SCW arthritis (Hamilton, 1983; Decker et el., 1984) is 
regulated, in part, by HBGF-1. 
Enhanced HBGF-1  immunostaining developed early  in 
both T-cell competent and incompetent LEW rats, but persis- 
tent high level staining of HBGF-1 was T-cell dependent, as 
is the disease process in general (Fig. 5). The induction of 
acute arthritis is not T-cell dependent, whereas the induction 
of chronic arthritis is T-cell dependent (Wilder et at., 1987). 
It is noteworthy that HBGF-1 was immunolocalized in cells 
throughout the diseased extremities of  arthritic rats including 
bone marrow, bone, cartilage, synovium, and ligamentous 
and tendinous structures (Fig. 5, B-E). Surprisingly, we also 
observed significant  HBGF-1 polypeptide immunostaining in 
the skin of the arthritic rats (Fig. 5 H). These observations 
serve as an alternative control for the immunohistocbemical 
analysis because HBGF-1 staining in the rat before the induc- 
tion of arthritis was minimal at best. However, 28 d after the 
initiation of  arthritis, HBGF-I staining remained readily visi- 
ble in the skin; an observation that parallels the staining of 
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HBGF-1  in the epidermis is consistent with the observation 
that HBGF-I can stimulate the proliferation of keratinocytes 
in vitro (Fourtanier  et al.,  1986; Shipley et al.,  1989).  Fur- 
ther, these observations implicate HBGF-1  in the physiology 
of dermal blood vessels, hair follicles, and keratinocytes and 
suggest that HBGF-1  may also play a role in dermal wound 
and ulcer healing, hair growth and reepithelization in vivo. 
The apparent  presence of I-IBGF-1 within the nucleus of 
a wide variety of cells in situ is also noteworthy. At the pres- 
ent time, we do not know the significance of nuclear HBGF-1 
or the mechanism by which nuclear translocation  is achieved. 
However, HBGF-2 has been detected using immunological 
methods in the nucleus (Bouche et al.,  1987), and HBGF-1 
(Friesel and Maciag,  1988) and HBGF-2 (Moscatelli, 1988) 
remain structurally  intact for relatively long periods of time 
following receptor-mediated  endocytosis  in vitro.  Further, 
the detection of HBGF-1  as  a  predominantly  intracellular 
polypeptide is consistent with the signal peptide-less struc- 
ture of the HBGF-1 precursor (Jaye et al., 1986). It is possi- 
ble that HBGF-1  was also associated with the extracellular 
matrix but was in form not readily accessible to immunologi- 
cal detection. I-1BGF-2 has been detected in the extracellular 
matrix in vitro and in vivo (Vlodavsky et al.,  1987; Mosca- 
telli and Rifldn,  1988;  Folkman et al.,  1988) and heparin 
protects HBGF-2 from proteolytic modification (Saksela et 
al.,  1988)  in a  manner  similar to the protection afforded 
HBGF-1 (Rosengart et al., 1988). Our data do not complete- 
ly eliminate the possibility that HBGF-1 is present within the 
extracellular matrix (especially next to blood vessels where 
the intensity of staining may mask this detail). However, our 
data demonstrate that HBGF-1  does not reside in the base- 
ment membrane. In addition, HBGF-2 has been detected in 
macrophages (Baird et al., 1985), and we observed the pres- 
ence of HBGF-1  as an intracellular polypeptide in mononu- 
clear cells within the human RA and rat SCW arthritic  tis- 
sue in vivo.  Thus, while it is possible that the intracellular 
HBGF-1  detected by our antibody may be derived from the 
translation of the HBGF-1  mRNA transcript  and/or proteo- 
lytic extraction from sites within the extracellular matrix, the 
exaggerated  immunostaining of HBGF-1 in the mononuclear 
cell infiltrate suggests that HBGF-1  may also be delivered to 
the inflammatory site by these cells. 
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